###### 

**Appendix**: Supplementary tables A-C

###### 

Click here for additional data file.

Introduction
============

The increasing use of antibiotics has coincided with a rise in childhood asthma.[@ref1] [@ref2] This has triggered a surge of observational studies investigating the potential harmful role of exposure to antibiotics in fetal life[@ref3] [@ref4] [@ref5] [@ref6] [@ref7] and childhood[@ref6] [@ref7] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] on subsequent development of wheeze and asthma. Earlier results, however, are conflicting, possibly because of different selection of populations, study designs, and potential bias. Previous studies that have found positive associations between antibiotic exposure in fetal life and childhood asthma have hypothesised that treatment of the mother with antibiotics during pregnancy could trigger a disease process in perinatal life in susceptible individuals.[@ref3] [@ref4] [@ref5] Some studies have also suggested that a causal association between antibiotic exposure in childhood and asthma is plausible[@ref8] [@ref9] [@ref10] and, in line with the microflora hypothesis, that exposure to antibiotics could lead to an increased incidence of allergic disease such as asthma.[@ref21]

Systematic reviews have highlighted that the associations between antibiotic exposure and asthma could be caused by bias.[@ref22] [@ref23] Confounding by indication implies that the association is confounded by a third factor (such as respiratory infections) that could be the indication for antibiotic use and a risk factor for asthma,[@ref24] whereas reverse causation indicates that first occurrences of symptoms of asthma (associated with respiratory infections) have been treated with antibiotics, thereby inducing an association between antibiotics and asthma. Lack of adjustment for residual familial factors---for example, genetic and environmental confounding factors shared within families such as a genetic predisposition to respiratory infections and asthma, consultation patterns or other lifestyle and home environmental factors---is another potential source for bias.[@ref17] [@ref25] Some studies have suggested that the association between antibiotics and asthma might be confounded by indication or reverse causation[@ref11] [@ref12] [@ref13] [@ref14] [@ref16] [@ref17] or consultation patterns.[@ref3] [@ref15] [@ref18] To date, however, no study has investigated the association between exposure to antibiotics measured from the start of pregnancy and childhood asthma, taking familial factors into account.

Sibling studies provide the opportunity to study the association between antibiotics and asthma, with adjustment for familial factors.[@ref25] Full siblings share half of their genes, some intrauterine exposures, and parental factors and can be discordant regarding exposure to antibiotics. If associations seen in a cohort of siblings remain when non-affected siblings are used as controls for the affected children, then factors specific to each individual (such as the indication for antibiotic treatment) are assumed to be involved in the underlying causal pathways. On the contrary, if the association disappears or is diluted, it indicates that factors common to the siblings (such as parental factors) are involved.

We examined the association between exposure to antibiotics in fetal life or childhood and subsequent development of asthma by examining a prospective nationwide cohort of children followed from start of their mother's pregnancy up to school age. By exploring the association within families using sibling controls, we adjusted for familial factors, thereby further assessing causality. We studied the possibility of confounding by indication and reverse causation from respiratory infections by investigating whether specific groups of antibiotics (as a proxy for the indication of the treatment) were associated with asthma.

Method
======

Study population and design
---------------------------

This nationwide population based register study included Swedish children born to women who were pregnant between July 2005 and December 2010, identified from the Medical Birth Register. The cohort was linked to the Multi-Generation Register with the Swedish personal identity number to identify parents and siblings. The personal identity number enables unambiguous linkage between the registers held by the Swedish National Board of Health and Welfare and Statistics Sweden.

Variables
---------

We collected information on exposure and outcome from the Swedish Prescribed Drug Register, which contains complete data on dispensed drugs since July 2005, and the National Patient Register with complete nationwide information on all inpatient diagnoses since 1987 and specialist outpatient diagnoses since 2001.

### Exposure

Information on generic names and dates of filled prescriptions of systemic antibiotics (Anatomical Therapeutic Chemical (ATC) classifications system code J01A-J01X) was retrieved from the Swedish Prescribed Drug Register from July 2005 to the end of follow-up. All antibiotics were divided into three groups, modified from Marra and colleagues[@ref10] and as described elsewhere[@ref6] [@ref13]: "any antibiotics" included any type of antibiotics; "airway antibiotics" included antibiotics used to treat respiratory infections (amoxicillin, penicillin, cephalosporin, and macrolides), and "urinary tract or skin and soft tissue antibiotics" (pivmecillinam, trimethoprim, sulphonamide, ciprofloxacin, norfloxacin, nitrofurantoin, cloxacillin, flucloxacillin, and dicloxacillin).

### Outcome

Children were classed as having asthma if they had a diagnosis of asthma (ICD-10 (international classification of diseases, 10th revision) J45) registered in the National Patient Register and fulfilled one or both of two criteria for asthma drugs (ATC: R03) from the Swedish Prescribed Drug Register: two or more dispensed inhaled corticosteroids, leukotriene receptor antagonists, or fixed combinations of β2 agonists and corticosteroids, with gaps of two or more weeks between distributions or three or more dispensed asthma drugs as previously mentioned or short acting β2 agonists within a year.[@ref26] Date of onset was set as the date of prescription of any of the drugs or date of diagnosis, whichever came first.

### Other variables

We collected information on child's birth year, sex, birth weight (grams), gestational age (days), mode of delivery (vaginal, instrumental, emergency, or elective caesarean section), maternal smoking at first visit to the antenatal care clinic (yes/no), respiratory diagnosis as newborn (ICD-10: P22-P28), maternal age at delivery, parity (child's birth order), family situation (mother cohabits with child's father, or other), mother's country of birth (Sweden, other Nordic countries, or other) from the Medical Birth Register, which includes data on more than 98% of all births in Sweden. The highest level of education of either parent (0-9, 10-12, \>12 years) was retrieved from the Longitudinal integration database for health insurance and labour market studies. Maternal asthma was defined as the mother having either fulfilled the criteria of dispensed asthma drugs or a diagnosis of asthma during the study period.

Start date of pregnancy was estimated as the date of birth minus gestational age in days. Duration of pregnancy was further divided into three trimesters (first: 1-91 days; second: 92-189 days; third: ≥190 days). To ensure full coverage of exposure to antibiotics during fetal life and childhood from the Swedish Prescribed Drug Register, we restricted the cohort to children from pregnancies with an estimated start date of pregnancy as on or after 1 July 2005. Information on date of migration and death was collected from the Total Population Register. We excluded 9631 children born to women who migrated to Sweden during the pregnancy.

Statistical analysis
--------------------

The analyses were performed in two steps. Firstly, we analysed the association between antibiotic exposure and asthma in the whole cohort of children using Cox proportional hazard regression, with attained age as analysis time scale and sandwich estimator of standard errors to account for clustering within sibling groups. Follow-up was censored at study outcome, emigration, death, or end of study period (31 December 2011), whichever occurred first. Exposure to antibiotics in childhood was included in the model as a time (age) varying exposure. The proportional hazards assumption was tested with Schoenfeld's residuals. Non-proportional hazards were found for childhood exposure to antibiotics. Consequently, we allowed for time varying effects.

Secondly, we used a sibling control design to adjust for familial factors. For the controls we used all full siblings (excluding 9896 children for whom the father's identity was unknown) who did not have the outcome of interest yet and who were still in the study at the at which the index child developed asthma. While all siblings with discordant outcomes contribute to the hazard ratio estimates of the covariates, only siblings who are also discordant on exposure are informative for the estimation of the hazard ratios for the exposure. Thus, for tabulated frequencies in the sibling control analyses we report the number of families with siblings discordant on both outcome and exposure. There were one to four controls per case and cases without eligible sibling controls were excluded. We used a stratified Cox proportional hazard model conditional on sibling group to analyse the sibling control design data.

Results are reported both as crude and adjusted for maternal smoking during pregnancy, parity, family situation (cohort and sibling analyses), mother's country of birth, parental education, and maternal asthma (only cohort) for the analyses of antibiotic exposure in fetal life. Analyses of exposure to antibiotics in childhood were adjusted for child's sex, birth weight, gestational age, mode of delivery, respiratory diagnosis as newborn, maternal age at delivery, parity, family situation, maternal antibiotic exposure in fetal life (cohort and sibling analyses), and mother's country of birth, parental education (only cohort) and for interaction between age and parity (only sibling analyses).

We performed subanalyses to explore the association of exposure during first, second, and third trimester of the pregnancy and asthma, and between exposure to antibiotics in the first year of life and incident asthma from the age of 2.

A Poisson regression model, with restricted cubic splines (six knots) for time since first antibiotic exposure, was fitted to further assess potential reverse causation.

### Sensitivity analyses

The Swedish Prescribed Drug Register reports only on antibiotics dispensed outside hospitals and most of antibiotics in Sweden (90%) are captured in the register.[@ref27] In a sensitivity analysis, however, we included in the group "any antibiotics" those children who had been admitted to hospital and given a diagnosis previously shown to have a high correlation with antibiotic treatment.[@ref28] The effect of antibiotic exposure on asthma in the full cohort was further investigated by inclusion of interaction terms between birth order (first born compared with not first born) and antibiotic exposure. The association between antibiotics in childhood and asthma was further tested for a dose-response relation between number of prescriptions (0, 1, 2-3, or ≥4 as a continuous variable) and asthma. All analyses of exposure to antibiotics in fetal life and childhood and subsequent asthma were also analysed with asthma drug and diagnosis separately and further restricted to mothers born in Sweden.

All analyses were performed with Stata statistical software, version 13.

Results
=======

Figure 1 shows the final study populations for the cohort and sibling control analyses[](#fig1){ref-type="fig"}. We included 493 785 children in the cohort analyses, and 180 894 were eligible for the sibling control analyses. During the study period 4922 children emigrated and 1448 died. Tables 1 and 2 show the prevalence of asthma by cohort characteristics for the full cohort and for the sibling cohort[](#tbl1){ref-type="table"} [](#tbl2){ref-type="table"}. Overall, 6% of the children in the cohorts were defined as having asthma. In total, 20% of the children in the full cohort and 16% of the children in the sibling cohort had been exposed to antibiotics in fetal life, and at least one prescription of any antibiotic during childhood was filled for 62% of children in both cohorts. An additional 4% of children in both cohorts were assumed to have been exposed to antibiotics in hospital.

![**Fig 1** Final study populations for cohort and sibling control analyses. \*Estimated first start of pregnancy 1 July 2005; first child born on 8 January 2006. †93% of families had two children; 7% of families had three to five children; 12 364 were twins and 267 were triplets. Registers at National Board of Health and Welfare: MBR=Medical Birth Register; SPDR=Swedish Prescribed Drug Register; NPR=National Patient Register. Registers at Statistics Sweden: TPR=Total Population Register; LISA=Longitudinal integration database for health insurance and labour market studies; MGR=Multi-Generation Register](orta021540.f1_default){#fig1}

###### 

 Characteristics of children in full cohort and sibling cohort in analysis of association between fetal and childhood exposure to antibiotics and development of asthma

                                                 Full cohort                  Sibling cohort             
  ---------------------------------------------- ------------- -------------- ---------------- --------- --------------
  Total No of children                           493 785       29 753 (6.0)                    180 894   11 260 (6.2)
  Birth year:                                                                                            
   2006                                          73 865        5795 (7.9)                      30 434    2 241 (7.4)
   2007                                          101 323       7765 (7.7)                      36 350    2 603 (7.2)
   2008                                          103 467       7278 (7.0)                      36 184    2 495 (6.9)
   2009                                          104 967       5930 (5.7)                      35 553    2 337 (6.6)
   2010                                          110 163       2985 (2.7)                      42 373    1 584 (3.7)
  Sex:                                                                                                   
   Male                                          254 020       19 093 (7.5)                    93 380    7 377 (7.9)
   Female                                        239 765       10 660 (4.5)                    87 514    3 883 (4.4)
  Birth weight (g):                                                                                      
   \<2500                                        21 183        2374 (11.2)                     10 262    1 134 (11.1)
   2500-2999                                     54 499        3659 (6.7)                      20 940    1 501 (7.2)
   3000-3499                                     157 486       9021 (5.7)                      55 717    3 379 (6.1)
   3500-3999                                     169 582       9393 (5.5)                      61 023    3 374 (5.5)
   4000-4499                                     72 722        4113 (5.7)                      26 370    1 470 (5.6)
   ≥4500                                         17 600        1130 (6.4)                      6 314     386 (6.1)
   Missing                                       713           63 (8.8)                        268       16 (6.0)
  Gestational age at delivery (weeks):                                                                   
   ≤34                                           12 546        1771 (14.1)                     6 023     816 (13.6)
   35-36                                         17 356        1588 (9.2)                      7 634     709 (9.3)
   37-38                                         96 821        6903 (7.1)                      36 841    2 685 (7.3)
   39-40                                         248 414       13 546 (5.5)                    90 414    4 975 (5.5)
   ≥41                                           118 648       5945 (5.0)                      39 982    2 075 (5.2)
  Respiratory diagnosis at birth\*:                                                                      
   No                                            480 799       28 382 (5.9)                    175 955   10 706 (6.1)
   Yes                                           12 986        1371 (10.6)                     4 939     554 (11.2)
  Antibiotic exposure in fetal life†:                                                                    
   Any antibiotics                               101 135       7642 (7.6)                      28 939    2 178 (7.5)
   Airway antibiotics                            65 213        5208 (8.0)                      18 971    1 430 (7.5)
   Urinary tract/skin antibiotics                44 525        3259 (7.3)                      11 668    900 (7.7)
  Antibiotic exposure in childhood‡:                                                                     
   Any antibiotics                               305 938       25 306 (8.3)                    112 795   9 414 (8.4)
   Airway antibiotics                            292 173       24 859 (8.5)                    107 716   9 232 (8.6)
   Urinary tract/skin antibiotics                64 676        5922 (9.2)                      23 721    2 132 (9.0)
  Antibiotics assumed from hospital diagnosis§   21 413        3438 (16.1)                     7 885     1 246 (15.8)

\*ICD-10: respiratory distress of the newborn (P22), congenital pneumonia (P23), neonatal aspiration syndromes (P24), interstitial emphysema and related conditions originating in perinatal period (P25), pulmonary haemorrhage originating in perinatal period (P26), chronic respiratory disease originating in perinatal period (P27), and other respiratory conditions originating in perinatal period (P28).

†At least one antibiotic prescription to mothers during estimated duration of pregnancy.

‡At least one antibiotic prescription/hospital diagnosis associated with antibiotics in childhood.

§ICD-10: appendicitis (K35), sepsis (A40-A41), meningitis (A87, G00-G03), pneumonia (J18), skin infection (L08), cystitis (N30), and pyelonephritis (N10).

###### 

 Maternal characteristics in full cohort and sibling cohort in analysis of association between fetal and childhood exposure to antibiotics and development of asthma

                                                 Full cohort                  Sibling cohort             
  ---------------------------------------------- ------------- -------------- ---------------- --------- --------------
  Total No of children                           493 785       29 753 (6.0)                    180 894   11 260 (6.2)
  Mode of delivery:                                                                                      
   Vaginal                                       366 662       20 712 (5.7)                    136 452   7 870 (5.8)
   Instrumental                                  38 333        2235 (5.8)                      12 746    814 (6.4)
   Elective caesarean section                    37 934        2911 (7.7)                      17 893    1 054 (7.7)
   Emergency caesarean section                   50 569        3880 (7.7)                      13 687    1 518 (8.5)
   Missing                                       287           15 (5.2)                        116       4 (3.5)
  Smoking during pregnancy:                                                                              
   No                                            439 962       25 516 (5.8)                    162 490   9 806 (6.0)
   Yes                                           32 743        2766 (8.5)                      10 184    877 (8.6)
   Missing                                       21 080        1471 (7.0)                      8 220     577 (7.0)
  Age at delivery (years):                                                                               
   \<19                                          7746          462 (6.0)                       1 972     149 (7.6)
   19-24                                         61 960        3954 (6.4)                      23 118    1 660 (7.2)
   25-29                                         140 790       8873 (6.3)                      56 079    3 727 (6.7)
   30-34                                         173 923       10 395 (6.0)                    66 494    3 907 (5.9)
   ≥35                                           109 366       6069 (5.6)                      33 231    1 817 (5.5)
  Parity (at current delivery):                                                                          
   1                                             216 643       11 869 (5.5)                    65 781    4 287 (6.5)
   2                                             181 919       11 805 (6.5)                    80 583    4 767 (5.9)
   3                                             66 979        4200 (6.3)                      22 647    1 386 (6.1)
   ≥4                                            28 244        1879 (6.7)                      11 883    820 (6.9)
  Family situation:                                                                                      
   Mother and father cohabit                     444 030       26 454 (6.0)                    165 892   10 205 (6.2)
   Mother lives alone, other                     27 164        1761 (6.5)                      6 279     452 (7.2)
   Missing                                       22 591        1538 (6.8)                      8 723     603 (6.9)
  Country of birth:                                                                                      
   Sweden                                        393 578       25 007 (6.4)                    148 548   9 562 (6.4)
   Other Nordic countries                        7561          448 (5.9)                       2 649     174 (6.6)
   Other                                         92 646        4298 (4.6)                      29 697    1 524 (5.1)
  Parents' highest level of education (years):                                                           
   0-9                                           24 141        1576 (6.5)                      8 023     557 (6.9)
   10-12                                         180 539       12 239 (6.8)                    62 781    4 305 (6.9)
   \>12                                          286 922       15 874 (5.5)                    109 666   6 386 (5.8)
   Missing                                       2183          64 (2.9)                        424       12 (2.8)
  Maternal asthma:                                                                                       
   No                                            453 278       24 733 (5.5)                    162 887   9 113 (5.6)
   Yes                                           40 507        5020 (12.4)                     18 007    2 147 (11.9)

Antibiotics in fetal life
-------------------------

Table 3 shows the crude and adjusted hazard ratios and 95% confidence intervals for the association between antibiotics in fetal life and childhood asthma in the cohort and sibling control analyses[](#tbl3){ref-type="table"}. The crude cohort analyses showed that any antibiotics in fetal life was significantly associated with a 36% increased risk of asthma in childhood. There was a comparable increased risk for airway antibiotics (hazard ratio 1.41, 95% confidence interval 1.37 to 1.46). The excess risk associated with urinary tract/skin antibiotics was somewhat lower, but still significantly associated with asthma (1.25, 1.20 to 1.30). After adjustment for confounding variables, antibiotic exposure in fetal life remained significantly associated with asthma but reduced for any and airway antibiotics. In the sibling control analyses, the association disappeared; the adjusted hazard ratio was 0.98 (0.90 to 1.07) for airway antibiotics and 0.98 (0.88 to 1.10) for urinary tract/skin antibiotics. We found no difference in the hazard ratios (cohort and sibling control analyses) between trimesters for any group of antibiotics.

###### 

 Hazard ratios (HR) and 95% confidence intervals for asthma in relation to exposure to antibiotics in fetal life, overall and by trimester, in full cohort of children and for children with siblings

  Groups of antibiotics    All children\*                              Children with siblings                                         
  ------------------------ --------------------- --------------------- ------------------------ ------- --------------------- ------- ---------------------
  **Any**                                                                                                                             
  Overall                  1.36 (1.32 to 1.39)   1.28 (1.25 to 1.32)                            2799    1.00 (0.94 to 1.08)   2523    0.99 (0.92 to 1.07)
  Trimester:                                                                                                                          
   1                       1.35 (1.30 to 1.40)   1.29 (1.23 to 1.34)                            1 081   1.07 (0.95 to 1.20)   965     1.09 (0.97 to 1.23)
   2                       1.39 (1.34 to 1.44)   1.30 (1.25 to 1.35)                            1 312   0.99 (0.90 to 1.10)   1 171   0.97 (0.87 to 1.08)
   3                       1.33 (1.28 to 1.39)   1.26 (1.21 to 1.31)                            1 913   0.95 (0.85 to1.06)    1 078   0.95 (0.84 to 1.06)
  **Airway**                                                                                                                          
  Overall                  1.41 (1.37 to 1.46)   1.31 (1.27 to 1.35)                            1971    0.99 (0.91 to 1.07)   1773    0.98 (0.90 to 1.07)
  Trimester:                                                                                                                          
   1                       1.51 (1.43 to 1.58)   1.40 (1.33 to 1.47)                            656     1.09 (0.94 to 1.26)   588     1.11 (0.95 to 1.30)
   2                       1.45 (1.39 to 1.51)   1.33 (1.27 to 1.39)                            863     0.97 (0.86 to 1.10)   768     0.97 (0.85 to 1.11)
   3                       1.33 (1.27 to 1.39)   1.24 (1.18 to 1.30)                            817     0.95 (0.83 to 1.09)   738     0.96 (0.84 to 1.11)
  **Urinary tract/skin**                                                                                                              
  Overall                  1.25 (1.20 to 1.30)   1.23 (1.18 to 1.28)                            1209    1.01 (0.91 to 1.12)   1087    0.98 (0.88 to 1.10)
  Trimester:                                                                                                                          
   1                       1.16 (1.09 to 1.23)   1.15 (1.08 to 1.22)                            437     1.07 (0.90 to 1.28)   391     1.10 (0.91 to 1.33)
   2                       1.30 (1.23 to 1.37)   1.26 (1.19 to 1.33)                            544     0.99 (0.85 to 1.16)   485     0.93 (0.78 to 1.10)
   3                       1.31 (1.24 to 1.39)   1.28 (1.21 to 1.36)                            460     0.94 (0.79 to 1.12)   415     0.92 (0.76 to 1.10)

\*Excludes children born to mothers with prescriptions for antibiotics without license in Sweden during study period (n=9).

†23 900 000 person years and 29 745 events. Individuals with reported event before date of entry (birth) were excluded (n=8).

‡22 600 000 person years and 28 055 events.

§Adjusted for maternal smoking during pregnancy, parity, family situation (cohort and sibling analyses), and mother's country of birth, parental education, maternal asthma (cohort analyses), and age as analysis time scale. Individuals with missing information on included variables excluded.

¶All families discordant on asthma are included in analyses, but only those also discordant on exposure contribute to estimates in table therefore number of cases is number of families with siblings discordant for both antibiotic exposure and asthma.

Antibiotics during childhood
----------------------------

Tables 4 and 5 show the crude and adjusted hazard ratios and 95% confidence interval for asthma in relation to any antibiotics in different age bands in the full cohort and sibling control analyses[](#tbl4){ref-type="table"} [](#tbl5){ref-type="table"}. The highest risk was found among the youngest children (adjusted hazard ratio 3.71, 95% confidence interval 3.41 to 4.03), and risk decreased with age (table 4). In the sibling control analyses all estimates were clearly lower than in the cohort analyses (2.11, 1.61 to 2.76, in the youngest children) (table 5). We found similar estimates in sensitivity analyses including children with presumed antibiotic exposure in hospitals in the group any antibiotics.

###### 

 Hazard ratios (HR) and 95% confidence interval for asthma in relation to age at exposure to any antibiotics in childhood in full cohort of children

  Age (years)   Crude          Adjusted \*              Adjusted†                                                
  ------------- ------- ------ --------------------- -- ----------- ------ --------------------- -- ----- ------ ---------------------
  0-0.5         245     4996   3.97 (3.66 to 4.30)      233         4715   3.71 (3.41 to 4.03)      233   4715   3.78 (3.48 to 4.10)
  0.5-1         241     8753   2.74 (2.61 to 2.87)      229         8294   2.59 (2.47 to 2.72)      229   8294   2.61 (2.49 to 2.74)
  1-1.5         224     6486   2.43 (2.31 to 2.55)      213         6133   2.31 (2.20 to 2.43)      213   6133   2.32 (2.20 to 2.44)
  1.5-2         194     4595   2.17 (2.04 to 2.31)      183         4337   2.06 (1.93 to 2.19)      183   4337   2.06 (1.93 to 2.20)
  ≥2            655     4915   1.90 (1.77 to 2.03)      612         4601   1.80 (1.68 to 1.93)      612   4601   1.81 (1.69 to 1.94)

\*Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at delivery, parity, family situation, maternal antibiotic exposure in fetal life, mother's birth country, parental education, and age as analysis time scale. Individuals with reported event before date of entry (birth) were excluded (n=312). Individuals with missing information on included variables excluded.

†Additionally adjusted for antibiotic exposure defined from hospital diagnoses.

###### 

 Hazard ratios (HR) and 95% confidence interval for asthma in relation to age at exposure to any antibiotics in childhood in children with siblings

  Age (years)   Crude                         Adjusted\*          Adjusted†                       
  ------------- ------- --------------------- ------------ ------ --------------------- -- ------ ---------------------
  0-0.5         1109    1.89 (1.49 to 2.41)                993    2.11 (1.61 to 2.76)      830    2.23 (1.71 to 2.91)
  0.5-1         1704    1.51 (1.34 to 1.71)                1541   1.46 (1.28 to 1.67)      1337   1.47 (1.29 to 1.68)
  1-1.5         955     1.77 (1.53 to 2.04)                859    1.82 (1.55 to 2.13)      768    1.80 (1.53 to 2.11)
  1.5-2         547     1.46 (1.18 to 1.80)                498    1.50 (1.19 to 1.89)      462    1.51 (1.20 to 1.91)
  ≥2            600     1.32 (0.99 to 1.76)                556    1.32 (0.97 to 1.79)      507    1.31 (0.96 to 1.78)

\*Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at delivery, parity, family situation, maternal antibiotic exposure in fetal life, age as analysis time scale, and parity included as interaction term with age. Individuals with missing information on included variables excluded.

†Additionally adjusted for antibiotic exposure defined from hospital diagnoses.

‡All families discordant on asthma are included in analyses, but only those also discordant on exposure contribute to estimates in table, therefore number of cases is number of families with siblings discordant for both antibiotic exposure and asthma.

Table 6 and 7 show the associations between airway and urinary tract/skin antibiotics and subsequent asthma[](#tbl6){ref-type="table"} [](#tbl7){ref-type="table"}. For both groups of antibiotics, the cohort analyses showed a decreased hazard ratio with increasing age, but the difference in risk was more pronounced after exposure to airway antibiotics (adjusted hazard ratio 4.12, 95% confidence interval 3.78 to 4.50) compared with urinary tract/skin antibiotics (1.54, 1.24 to 1.92) in the youngest children (table 6[](#tbl6){ref-type="table"}). In the sibling control analyses, the estimates were clearly decreased compared with the cohort analyses, where the association with airway antibiotics remained significant (2.36, 1.78 to 3.13), and the association between urinary tract/skin antibiotics and asthma disappeared (0.85, 0.47 to 1.55) (table 7[](#tbl7){ref-type="table"}).

###### 

 Hazard ratios (HR) and 95% confidence intervals for asthma in relation to age at exposure to airway and urinary tract/skin antibiotics in childhood in full cohort of children

  Age (years)   Airway antibiotics\*                         Urinary tract/skin antibiotics\*                         
  ------------- ---------------------- --------------------- ---------------------------------- --------------------- ---------------------
  0-0.5         4.46 (4.10 to 4.86)    4.12 (3.78 to 4.50)                                      1.64 (1.33 to 2.03)   1.54 (1.24 to 1.92)
  0.5-1         2.83 (2.70 to 2.97)    2.65 (2.52 to 2.78)                                      1.60 (1.43 to 1.79)   1.54 (1.38 to 1.72)
  1-1.5         2.49 (2.37 to 2.61)    2.34 (2.23 to 2.47)                                      1.41 (1.27 to 1.56)   1.37 (1.23 to 1.53)
  1.5-2         2.20 (2.07 to 2.34)    2.07 (1.94 to 2.20)                                      1.22 (1.09 to 1.36)   1.19 (1.07 to 1.34)
  ≥2            1.91 (1.79 to 2.04)    1.79 (1.68 to 1.92)                                      1.21 (1.11 to 1.32)   1.20 (1.10 to 1.31)

\*Person time and number of events in cohort analyses of airway and urinary tract/skin antibiotics, same as for table 4 any antibiotics. Individuals with reported event before date of entry (birth) were excluded (n=312).

†Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at delivery, parity, family situation, maternal exposure to antibiotics in fetal life, mother's country of birth, parental education, and age as analysis time scale. Individuals with missing information on included variables excluded.

###### 

 Hazard ratios (HR) and 95% confidence intervals for asthma in relation to age at exposure to airway and urinary tract/skin antibiotics in childhood for children with siblings

  Age (years)   Airway antibiotics                         Urinary tract/skin antibiotics                                                                        
  ------------- -------------------- --------------------- -------------------------------- ------ --------------------- -- ----- --------------------- -- ----- ---------------------
  0-0.5         1075                 2.16 (1.68 to 2.79)                                    961    2.36 (1.78 to 3.13)      129   0.70 (0.41 to 1.20)      114   0.85 (0.47 to 1.55)
  0.5-1         1655                 1.56 (1.37 to 1.77)                                    1494   1.51 (1.31 to 1.73)      255   0.93 (0.71 to 1.21)      226   0.94 (0.70 to 1.25)
  1-1.5         931                  1.85 (1.59 to 2.14)                                    837    1.91 (1.62 to 2.24)      234   0.98 (0.73 to 1.30)      216   0.98 (0.72 to 1.33)
  1.5-2         546                  1.50 (1.21 to 1.86)                                    496    1.54 (1.22 to 1.95)      175   1.02 (0.71 to 1.45)      161   0.98 (0.66 to 1.44)
  ≥2            628                  1.38 (1.04 to 1.84)                                    580    1.38 (1.02 to 1.86)      292   0.97 (0.67 to 1.41)      264   0.95 (0.63 to 1.42)

\*Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at delivery, parity, family situation, maternal exposure to antibiotics in fetal life, age as analysis time scale, and parity included as interaction term with age. Individuals with missing information on included variables excluded.

†All families discordant on asthma are included in analyses, but only those also discordant on exposure contribute to estimates in table, therefore number of cases is number of families with siblings discordant for both antibiotic exposure and asthma.

Table 8 and 9 shows the associations between antibiotic exposure in first year of life and incidence of asthma from the age of 2[](#tbl8){ref-type="table"} [](#tbl9){ref-type="table"}. We found significant associations for all groups of antibiotics with asthma in the cohort analyses, but no associations remained in the sibling control analyses.

###### 

 Hazard ratios (HR) and 95% confidence intervals for asthma from age 2 in relation to exposure to any, airway, and urinary tract/skin antibiotics in first year of life in full cohort of children

                       Crude\* HR (95% CI)   Adjusted†‡ HR (95% CI)
  -------------------- --------------------- ------------------------
  Any                  1.18 (1.11 to 1.26)   1.23 (1.15 to 1.32)
  Airway               1.19 (1.12 to 1.27)   1.24 (1.16 to 1.33)
  Urinary tract/skin   1.25 (1.08 to 1.43)   1.24 (1.08 to 1.44)

\*655 137 person years and 4915 events.

†612 270 person years and 4601 events.

‡Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at delivery, parity, family situation, maternal exposure to antibiotics in fetal life, mother's country of birth, parental education, and age as analysis time scale. Individuals with missing information on included variables excluded.

###### 

 Hazard ratios (HR) and 95% confidence intervals for asthma from age 2 in relation to exposure to any, airway, and urinary tract/skin antibiotics in first year of life for children with siblings

                       Crude                         Adjusted\*         
  -------------------- ------- --------------------- ------------ ----- ---------------------
  Any                  568     0.93 (0.70 to 1.23)                523   0.90 (0.66 to 1.23)
  Airway               550     0.98 (0.74 to 1.30)                505   1.01 (0.75 to 1.38)
  Urinary tract/skin   120     0.99 (0.56 to 1.74)                107   0.63 (0.32 to 1.25)

\*Adjusted for sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at delivery, parity, family situation, maternal exposure to antibiotics in fetal life, age as analysis time scale, and parity included as interaction term with age. Individuals with missing information on included variables excluded.

†All families discordant on asthma are included in analyses, but only those also discordant on exposure contribute to estimates in table, therefore number of cases is number of families with siblings discordant for both antibiotic exposure and asthma.

Figure 2 shows the hazard ratio for asthma in relation to time since first exposure to any, airway, and urinary tract/skin antibiotics in childhood[](#fig2){ref-type="fig"}. The hazard ratio for asthma in relation to any and airway antibiotics decreased steeply with time since exposure from about four to two during the first six months after antibiotic treatment. For urinary tract/skin antibiotics the hazard ratio slightly increased after exposure and then returned to the initial hazard ratio of around 1.25 in the years after exposure.

![**Fig 2** Adjusted hazard ratio and 95% confidence interval for asthma in relation to time (in years) since first exposure to various antibiotics in childhood. Hazard ratio adjusted for attained age, sex, birth weight, gestational age, mode of delivery, respiratory diagnoses as newborn, maternal age at delivery, parity, family situation, mother's country of birth, and parental education. UTI=urinary tract infection](orta021540.f2_default){#fig2}

Sensitivity analyses showed that first born children had a higher excess risk of asthma than subsequent children after exposure to any and airway antibiotics before 1.5 years of age (P\<0.001 for interaction between birth order and exposure) but not after exposure to urinary tract/skin antibiotics (P=0.38). In the full cohort, we found a dose-response relation for the association between increasing number of prescriptions for all groups of antibiotics and asthma (P\<0.001, all age groups). In sibling analyses, the dose-response relation remained for any and airway antibiotics (P\<0.001, all age groups), but not for urinary tract/skin antibiotics (P=0.22-0.97 for different age groups). Analyses restricted to mothers born in Sweden produced similar estimates (data not tabulated). Analyses repeated with asthma drugs and diagnosis as separate outcomes yielded comparable estimates (tables A-C in appendix).

Discussion
==========

Our results, based on a nationwide population based birth cohort, show a positive association between exposure to antibiotics in fetal life or childhood and subsequent asthma. In sibling control analyses, however, these associations disappeared or clearly decreased, indicating that the association might be strongly confounded by factors shared by families. To our knowledge, this is the first study to use sibling control analyses to assess the causality of the association between antibiotics and asthma. Our findings support the view that the association between fetal exposure to antibiotics and asthma is affected by confounding factors shared by siblings. We also found that the association between antibiotics for urinary tract/skin conditions in childhood and asthma disappeared in the sibling analyses. In analyses restricted to exposure during the first year of life and incident asthma from the age of 2, the association disappeared for all groups of antibiotics. This indicates that the association seen in the cohort is confounded both by familial factors and by indication or reverse causation.

Previous studies
----------------

Some previous studies have suggested that exposure to antibiotics in fetal life increases the risk of subsequent asthma and wheeze,[@ref3] [@ref4] [@ref5] whereas another study, with a fairly small study population, reported similar estimates but no significant associations.[@ref7] It has also been reported that the risk of transient early, persistent, and late onset wheezing differed by types of antibiotics, though exposure during pregnancy and wheezing outcomes were based on parental report and thus recall bias might have been a problem.[@ref4] In accordance with others we found similar risks of asthma regardless of trimester[@ref3] and groups of antibiotics,[@ref3] [@ref6] and the risk disappeared altogether in the sibling analyses.

Our results from the cohort analyses suggest that the excess risk of asthma after exposure to antibiotics in childhood decreases with increasing age.[@ref14] [@ref17] [@ref19] In addition, the excess risk decreases with time since first exposure to any and airway antibiotics independent of age at first exposure.[@ref17] In line with the microflora hypothesis,[@ref21] which suggests that antibiotics can disrupt the normal microflora-mediated mechanisms of immunological tolerance in the mucosa leading to an increased risk of allergic immune responses, it could be hypothesised that the impact of antibiotics on the gut microflora and development of the immune system is strongest in the first year of life or shortly after exposure.[@ref29]

Alternatively, our cohort results could be explained by difficulties in differentiating early wheezing caused by respiratory infections from asthma or obstructive bronchitis in young children.[@ref16] Consequently, first time symptoms of asthma might be treated with antibiotics, thereby inducing an association between antibiotics and asthma (reverse causation). Alternately, antibiotics were given to treat respiratory infection, in itself a risk factor for asthma, resulting in confounding by indication. Adjustment for respiratory infections has previously led to decreased risk estimates or loss of statistical significance, further supporting these potential sources of bias.[@ref9] [@ref11] [@ref14] [@ref20] We could not adjust for respiratory infections because the Swedish Prescribed Drug Register does not provide indication for the actual prescriptions, nor were we able to adjust for number of doctor's visits as visits in primary care are not recorded in the National Patient Register. Yet, based on previous studies[@ref6] [@ref13] and standardised treatment guidelines, we categorised antibiotics into those used to treat respiratory infections or not, and we confirm previous findings that airway antibiotics were associated with asthma, whereas urinary tract/skin antibiotics were not.[@ref13] Metsälä and colleagues recently found that the effect of urinary tract antibiotics on asthma, although not significant, was similar to the effect of airway antibiotics.[@ref6] Marra and colleagues found a significant risk of asthma independent of classes of antibiotics and an increasing risk with number of antibiotic courses administered.[@ref10] We also found an increased risk of asthma[@ref6] [@ref10] and a dose-response relation between number of prescriptions and asthma[@ref10] for any type of antibiotics in the cohort analyses. In the sibling analyses independent of timing of exposure, however, the association and dose-response relation disappeared for urinary tract/skin antibiotics. Furthermore, in sibling analyses restricted to exposure in first year of life, the associations disappeared for all groups of antibiotics. The discrepancy between our studies could be caused by variances in antibiotic prescription practices between countries or by our approach of adjusting for shared factors within families.

Having older siblings has been suggested to protect younger children from developing asthma.[@ref30] We found that firstborn children had a higher excess risk of asthma than subsequent children after exposure to any and airway antibiotics before the age of 1.5 years. There was no difference after exposure to urinary tract/skin antibiotics. These results support that the associations seen in the cohort, independent of birth order, are confounded by familial factors and by indication or reverse causation. In a study by Semic-Jusufagic and colleagues, the possibility of confounding by indication was further highlighted.[@ref17] The authors found that antibiotics given in early life were associated with an increased susceptibility to viral infections because of impaired antiviral immunity and also to genetic variants on chromosome 17q21 locus, which is strongly associated with asthma.[@ref31]

In the sibling control analyses we were able to adjust for residual genetic and environmental confounding factors shared by families, such as a genetic predisposition to respiratory viral infections and asthma, consultation patterns, lifestyle, and home environmental factors. Thus, even though we confirmed previous positive associations between antibiotic exposure in fetal life and childhood and asthma in our cohort analyses, the associations disappeared or clearly decreased in sibling control analyses, indicating that previous studies as well as our own cohort results might be confounded by familial factors. The remaining effect of airway antibiotics is most likely caused by confounding by indication or reverse causation, which is not accounted for in the sibling analyses. This is further supported by the subanalyses restricted to children exposed in first year of life and incident asthma from age 2, in whom the association disappeared for all groups of antibiotics.

Strengths and limitations
-------------------------

The strength of our study is the large dataset in which full siblings have been identified, allowing for analyses taking shared (unmeasured) factors within families into account. Furthermore, with objectively and prospectively collected measures of exposure and validated outcomes[@ref26] from population based registers, precluding recall bias, we were able to assess the association between antibiotics and asthma over time. In addition to information on prescribed antibiotics, we were also able to include information on assumed exposure to antibiotics in hospital. Moreover, our population based design means our findings are generalisable.

The study has some limitations. Firstly, we were not able to take adherence to treatment[@ref32] or delayed prescribing[@ref33] into account. Yet, exposure to antibiotics was defined as a filled prescription for antibiotics, which reduces the risk that delayed prescribing affected our results. Secondly, we were not able to control for antibiotics prescribed abroad, which could be relevant for children of mothers born outside Sweden, who might spend longer periods abroad, potentially leading to associations driven towards the null. Sensitivity analyses restricted to children of women born in Sweden, however, produced similar results. Thirdly, even with our large study population, the number of families discordant for both urinary tract/skin antibiotics in childhood and asthma were fewer than in the analyses of fetal exposure, yielding broader confidence intervals.

Conclusion and implications
---------------------------

In conclusion, our study suggests that the association between antibiotics and asthma is caused by confounding factors shared within families, in addition to confounding by indication or reverse causation because of respiratory infections. As there is a considerable threat from antibiotic resistance worldwide, it is of great importance to acknowledge that though antibiotics might not cause asthma, careful consideration is required as to whether respiratory symptoms should be treated with them.

### What is already known on this topic

1.  Numerous studies have reported conflicting results regarding the association between antibiotic exposure in fetal life and early childhood and subsequent development of asthma

2.  Bias from confounding by indication and reverse causation from respiratory infections could explain previous positive associations

3.  Lack of adjustment for residual genetic and environmental confounding factors shared by families is another potential source for bias, which has not been assessed to date

### What this study adds

1.  Cohort analyses showed an increased risk of asthma after antibiotic exposure in fetal life and childhood

2.  The risk for asthma was stronger after childhood exposure to antibiotics used to treat respiratory infections than for those used for urinary tract and skin infections, implying confounding by indication or reverse causation

3.  In the sibling analyses, the association between antibiotic exposure in fetal life and asthma disappeared, indicating that the association was affected by factors shared by siblings. For antibiotic exposure in childhood, the association disappeared for antibiotics used for urinary tract and skin infection and clearly decreased for antibiotics used for respiratory infections

4.  Cohort results and previous findings have been confounded by genetic and environmental factors shared by families in addition to cofounding by indication or reverse causation
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